Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization

AIDS Research and Human Retroviruses

Volumn 17, Issue 17, 2001, Pages 1645-1654

  McInerney, Tracey L ^a   Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL RECEPTOR; GLYCOPROTEIN GP 120; HUMAN MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOTHERAPY; LYMPHOBLASTOID CELL; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS ADSORPTION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; NEUTRALIZATION TESTS;

EID: 0035689826     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201753342059     Document Type: Article

References (53)

1. Update on the neutralisation of animal viruses
2. Postadsorption neutralization of poliovirus
3. Protective antibodies inhibit reovirus internalization and uncoating by intracellular proteases
4. Newcastle disease virus: The effect of monoclonal antibody in the overlay on virus penetration and the immunoselection of variants
5. A new mechanism for the neutralization of enveloped viruses by antiviral antibody
6. Mechanisms of rabies virus neutralization by glycoprotein specific monoclonal antibodies
7. Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55
8. Neutralization of respiratory syncytial virus after cell attachment
9. Neutralization of HIV-1: A binding/post-binding event mediated through the gp120 immunodominant epitope
10. HIV-neutralization: Evidence for rapid, binding/post-binding neutralization from infected humans, chimpanzees and gp120-vaccinated animals
11. Neutralizing antibody response during human immunodeficiency virus type 1 infection: Type and group specificity and viral escape
12. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1
13. Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp120: Identification of a very early fusion-independent event as a neutralization target
14. Mechanism of action of a 17 amino acid microantibody specific for the V3 loop that neutralizes free HIV-1 virions
15. Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the C-terminal tail of human immunodeficiency virus type 1
16. Replication of patient isolates of human immunodeficiency virus type 1 in T cells: A spectrum of rates and efficiencies of entry
17. Cellular proteins in HIV virions
18. The acquisition of host-encoded proteins by nascent HIV-1
19. Anti-HLA class I heavy chain monoclonal antibodies inhibit human immunodeficiency virus production by peripheral blood mononuclear cells
20. Influenza A virus interactions with murine lymphocytes. I. The influence of influenza virus A/Jap 305 (H2N2) on the pattern of migration of recirculating lymphocytes
21. An early post-infection signal mediated by monoclonal anti-beta2 microglobulin antibody is responsible for delayed production of human immunodeficiency virus type 1 in peripheral blood mononuclear cells
22. Inhibition of human immunodeficiency virus type 1 production in infected peripheral blood mononuclear cells by human leukocyte antigen class I-specific antibodies: Evidence for a novel antiviral mechanism
23. Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis
24. Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding
25. Identification of residues in human CD4 critical for the binding of HIV
26. Analysis of the site in CD4 that binds to the HIV envelope glycoprotein
27. Human immunodeficiency virus entry into T cells: More rapid escape from an anti-V3 loop than an antireceptor antibody
28. Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncytia formation but not in viral entry
29. An antibody that binds the CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells
30. Functional epitope analysis of the human CD4 molecule: Antibodies that inhibit immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region for CD4
31. The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4
32. An antibody that binds domain 1 of CD4 inhibits replication of HIV-1 but not HTLV-transformed cell line
33. Conformational transitions in CD4 due to complexation with HIV envelope glycoprotein gp120
34. A large array of human monoclonal antibodies to type 1 immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
35. Recombinant human antibodies: Linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture
36. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
37. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing monoclonal antibody against the gp120 CD4 binding site
38. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a post-fusion event
39. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization
40. Novel anti-CD4 monoclonal antibodies separate HIV infection and fusion of CD4+ cells from virus binding
41. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans
42. Recognition of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
43. Differences in affinity of anti-CD4 monoclonal antibodies predict their effects on syncytium induction by human immunodeficiency virus
44. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
45. The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: An approach to postexposure prophylaxis
46. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
47. HIV requires multiple gp120 molecules for CD4-mediated infection
48. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide
49. Treatment of rheumatoid arthritis with monoclonal antibody M-T151
50. Soluble human CD4 elicits an antibody response in rhesus monkeys that inhibits simian immunodeficiency virus replication
51. Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals
52. Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV-1-seropositive mothers: A follow-up study
53. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity